AMPLIFY-2NCT07881458
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Nov 2026 to Oct 16, 2026
- Site details revised at 75 of 75 sites
- Minor Site details revised at 1 of 75 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percent Change from Baseline in Body Weight
Timeframe: Baseline, Week 100
Secondary (21)
Change from Baseline in Waist Circumference
Change from Baseline in Hemoglobin A1c (HbA1c)
Change from Baseline in Systolic Blood Pressure
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Percent Change from Baseline in Total Body Fat Mass
Show 16 moreShow less
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in Fasting Glucose
Percentage of Participants who Achieve a Composite of Body Weight Reduction ≥ 15% and HbA1c <6.5%
Percent Change from Baseline in Total Cholesterol
Percent Change from Baseline in Fasting Insulin
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) Total Score
Change from Baseline in EQ-5D-5L Score
Change from Baseline in Eating Behaviors and Attitudes Questionnaire (EBAQ) Score
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight
Percentage of Participants with a Change in Medication Use
Overall Functional Assessment of Chronic Illness Therapy, Item GP5 (FACT-GP5) Score
Pharmacokinetics (PK): Maximum Concentration of Eloralintide at Steady State (Cmax,ss)
PK: Area Under the Concentration Versus Time Curve of Eloralintide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
PK: Maximum Concentration of Tirzepatide at Steady State (Cmax,ss)
PK: Area Under the Concentration Versus Time Curve of Tirzepatide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Arms and interventions
EloraTZPExperimental
Participants will receive EloraTZP subcutaneously (SC)
TirzepatideExperimental
Participants will receive tirzepatide SC
Drugs: eloralintide and tirzepatide, Tirzepatide
Sites
75 sites in 10 countries
United States 25, Romania 10, Spain 9, China 7, Brazil 6, Germany 6, Japan 5, South Korea 5, Puerto Rico 1, Taiwan 1